PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Trichomonas”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1975

[Cultivation of Trichomonas gallinarum and Trichomonas tenax on a trimed medium].

Studied was the possibility to isolate and culture Tr. gallinarum and Tr. tenax on a medium Trimed, proposed by the authors for the isolation and cultivation of Tr. vaginalis. The growth and development of the two Trichomonas species were followed up at various temperatures -- 38 degrees, 36 degrees, and 32 degrees C, in order to establish the most appropriate temperature for continuous cultivation at longer intervals of reseeding as well as the temperature optimum for the fast deposition of great amounts of biomass. It was found that the Trimed medium is suitable for the isolation and cultivation of Tr. gallinarum and Tr. tenax. Temperatures of 38 degrees and 36 degrees contribute to the accumulation of greater amounts of biomass, while at 32 degrees C the growth of these protozoa is delayed and reseeding is to be carried out at greater intervals.

Animals↗
PubMed1977

[Trichomonas vaginalis and cytological findings (author's transl)].

The detection of Trichomonas vaginalis by the method of the Papanicolaou smear has proven as suitable. Alterations of surface cells in the presence of Trichomonas vaginalis are described, and causal relations between atypic cells and Trichomonas vaginalis are discussed. From a total of 13000 in investigations of cancer screening in 1975, an infection with Trichomonas vaginalis was found in 850 cases = 6,69 p.c. In contrast to this result 28 p.c. of the 116 patients with cancer of precancer of the cervix uteri had a simultaneous infection with Trichomonas vaginalis. These results suggest the possibility of a relationship between the incidence of Trichomonas vaginalis and atypic cell alterations. Therefore it is necessary for the cytologist to search for Trichomonas vaginalis in cancer-screenings and to inform the gynaecologist in case of a positive finding. All exact posttherapeutic control is indicated to find out the presence of a potentially malignant atypia of cells or of reversible reactive cell alterations.

Adult↗
PubMed2026

Metagenomic Next-Generation Sequencing for the Diagnosis of Trichomonas Vaginalis-Associated Empyema: a Case Report and Literature Review.

BACKGROUND: This report describes a rare case of empyema caused by Trichomonas vaginalis co-infected with Streptococcus agalactiae and Streptococcus pyogenes, aiming to explore the role of T. vaginalis in the development of empyema, its diagnostic methods, and treatment strategies. METHODS: The patient was a 46-year-old male who presented with cough, sputum production, and shortness of breath. The diagnosis was made using chest CT, routine pleural fluid analysis, bacterial culture, and metagenomic next-generation sequencing (mNGS). Pleural fluid examination revealed numerous motile Trichomonas organisms, and bacterial culture identified Streptococcus agalactiae and Streptococcus pyogenes as the pathogens. Fur-ther mNGS confirmed these bacteria as the causative agents, with 39 Trichomonas sequences detected, including 32 sequences specific to T. vaginalis. RESULTS: The patient received combination antimicrobial therapy and underwent chest tube drainage and thoracoscopic empyema debridement. Post-treatment, the patient's condition significantly improved. A literature review revealed that while Trichomonas tenax is a common pathogen in empyema, T. vaginalis is an extremely rare cause. T. vaginalis infection may be associated with bacterial co-infections, immunosuppression, or poor hygiene. CONCLUSIONS: This case is the first report of T. vaginalis induced empyema, expanding the understanding of Trichomonas infections. Although such infections are rare, they should be considered in high-risk patients. Further studies are needed to investigate the infection pathways of T. vaginalis and its mechanisms of bacterial synergy in disease pathogenesis to improve clinical diagnosis and treatment strategies.

Humans↗
PubMed1979

In vivo and in vitro studies of tinidazole in Trichomonas vaginalis infection.

A total 787 patients with complaints of vaginal discharges were examined, of which 106 patients were found to be positive for Trichomonas vaginalis by the normal saline method, and 114 patients were positive by the culture method. In the in vivo series, 55 patients were treated with a single dose of 1.8 gm of tinidazole, and with a follow-up examination 7 days there after. For the in vitro study 55 swab specimens were cultured to study the tinidazole sensitivity of Trichomonas vaginalis. The survival of Trichomonas vaginalis at each concentration of tinidazole was presented as a cumulative frequency. At the concentration of 1 microgram/ml, none of the organisms were killed; but at the concentration of 6 micrograms/ml, the mortality rate was 100%. In the in vivo series a 100% cure rate was obtained with tinidazole with no side effects, and in vitro series the mean minimum trichomonicidal concentration (MCC) at 24 hours was 3.76 +/- 1.25 micrograms/ml, with the range of 2--6 micrograms/ml. These studies revealed the sensitivity of Trichomonas vaginalis to tinidazole in Thailand and that tinidazole at a single oral dose of 1.8 gm perferably after a meal is effective, safe and cheap for the treatment of Trichomonas vaginalis.

Adolescent↗
PubMedDate not supplied

[Significance of variations in the size of Trichomonas vaginalis in patients with dysplasia, intrapithelial and invasive planocellular carcinoma of the uterine cervix].

The study of the size of Trichomonas vaginalis in 100 patients with dysplasia and intraepithelial or invasive planocellular carcinoma of the uterine cervix and in 100 controls with trichomoniasis alone has shown that the parasites are of a significantly smaller diameter in carcinoma in situ (9.57 +/- 0.35 mu) and invasive carcinoma (10.44 +/- 0.66 mu) than in dysplasia (13.71 +/- 0.35 mu). The analysis of the variance has shown that this difference is statistically significant. In the control group with trichomoniasis alone, the diameter of Trichomonas vaginalis was twice as large (21.46 +/- 0.66 mu) as that in carcinoma and still larger than that in dysplasia. This indicates that small forms of Trichomonas vaginalis are more pathogenic than large ones and might be one of the causative agents of the atypical transformation of the squamous epithelium of the uterine cervix.

Carcinoma↗
PubMed1979

[Association between Trichomonas vaginalis and some types of lesions of the uterine neck based on data collected in the quinquennium of 1974--1978].

In our statistic the number of cases of vaginal trichomoniasi in which discariosi, displasie, metaplasie are found are represented in about 40%. While 37,5% of women affected with neoplastic lesions had Trichomonas vaginalis. It is certain that in the presence of flogosi from Trichomonas vaginalis we meet more frequently than normal, atipie cellulars and that often an exact valutation of this lesion is put back to an exam after the recovery of the Trichomonas vaginalis, because fortunately, more than often these disturbances disappear.

Cervix Uteri↗
PubMed1978

The influence of certain B12-antagonists upon trichomonas foetus.

The antagonistic substances used in our experiments showed various relationships to the pathogenic protozoa Trichomonas foetus. Theseinacid and L-2-Methyl-2-Aminoaethenole demonstrated comparable inhibiting influences on the Trichomonas population. Puriniribosid, 6-Mercaptopurine, 4-Mercaptopteridine and Decobald-Cobamide exercised no recognisable influence on the Trichomonas foetus.

Animals↗
PubMed1979

Serodiagnosis of Trichomonas vaginalis infection by the indirect fluorescent antibody test.

The indirect fluorescent antibody test was used to detect antibodies to Trichomonas vaginalis in 200 antenatal patients. A total of 104 (52%) gave a positive reaction with antigen prepared from cultures of trichomonas isolated from seven of the patients. Antitrichomonal antibody was detected at a 1/4 dilution in 90% of patients with proven trichomoniasis, while the highest dilution at which antibody was detected was 1/32. IgG rather than IgM appeared to be the antibody class involved. Of those patients with no demonstrable trichomonal infection, 17% gave positive reactions at 1/4 dilution, while 64% had no demonstrable antibody. One of 30 children under 11 years of age gave a positive reaction.

Antigens↗
PubMed1979

Strain of Trichomonas vaginalis resistant to metronidazole and other 5-nitroimidazoles.

A strain of Trichomonas vaginalis (IR-78), recently isolated from a patient afflicted with recurrent symptomatic trichomoniasis, showed resistance to metronidazole, tinidazole, and nimorazole in vitro as well as in vivo. In a serial dilution test using cysteine monohydrochloride-peptone-liver infusion-maltose medium, T. vaginalis IR-78 was only resistant under aerobic conditions. Under anaerobic conditions it was as susceptible as the normal reference strain. The minimal lethal concentrations of metronidazole, tinidazole, and nimorazole for IR-78 were 100, 50, and 50 mug/ml aerobically and 0.4, 0.4, and 0.2 mug/ml anaérobically, respectively. The efficacy of metronidazole, tinidazole, and nimorazole was assessed in vivo by oral administration to mice simultaneously infected with IR-78 both subcutaneously and intraperitoneally. The CD(50) (dose needed to cure 50% of infections) of each compound was significantly higher for the subcutaneous than for the intraperitoneal infection. In contrast, there was little difference in CD(50) for these infections in mice inoculated with a susceptible trichomonas strain. The CD(50)'s for all three compounds against intraperitoneal and subcutaneous infections with IR-78 were 2 to >70 times higher than for susceptible strain E. Both forms of infection with IR-78 could always be cured with therapeutically acceptable doses of tinidazole and nimorazole; subcutaneous infections could not be cured with tolerated doses of metronidazole.

Animals↗
PubMed1975

Involvement of a surface concanavalin A-binding glycoprotein in the adhesion of Trichomonas vaginalis to substrates.

Treatment of Trichomonas vaginalis with EDTA removes their ability to adhere to glass surfaces and changes their affinity to Concanavalin A (ConA) by a different distribution of their surface structures. Filtrates of the EDTA-treated Trichomonas passed through affinity chromatography columns (ConA bound to Sepharose 4B) separate into 2 fractions, one fraction was bound to the ConA-Sepharose beads, the other was not. The Con A - bound fraction appears to be a glycoprotein which restores in a specific way the ability of the EDTA-treated protozoa to adhere to glass.

Cell Adhesion↗
PubMed1979

[New fluorescence microscopic technic for the identification of Trichomonas vaginalis].

A new fluorescent dye for the identification of trichomonas vaginalis is described. Specimens under investigation were mixed with 4',6-diamidino-2-phenylindol (Dapi) and examined using white light and UV-light. The combined use of the two techniques allows to recognize the mobile non fluorescing and the dead intensive yellow fluorescing trichomonads. Devitalized epithelial cells, bacteria and leucocytes in contrast to living trichomonas are stained yellow in a few minutes. This is of diagnostic help.

Amidines↗
PubMed1978

Single-day treatment of trichomonas vaginitis with low dose of ornidazole.

A total of 107 cases of trichomonas vaginitis were treated with different regimens of ornidazole. The overall success rate of the treatment assessed by wet smear and clinical signs after three days in 68 cases was 98.5%. The side effects were mild and of short duration. These were noted in 14.7% of the assessable cases. No significant differences were seen in the success rate between the three drug regimens and the preliminary conclusions of the trial are that ornidazole is safe and effective in the treatment of trichomonas vaginitis in Korean women with an oral dose of 1.0 gm, 1.0 gm plus 0.5 gm intravaginally or 2.0 gm given in a single day.

Adult↗
PubMedDate not supplied

Evaluation of the indirect hemagglutination technique for study of Trichomonas vaginalis infections, particularly in men.

The indirect hemagglutination (IHA) technique was evaluated for use in the serologic study of infection with Trichomonas vaginalis. The IHA test showed that sera from 88% of women attending a venereal disease clinic had antibody to T. vaginalis. The antibody frequency and titers were highest in women who had documented infections due to T. vaginalis. Serologic and cultural evidence of recent or active trichomonal infection was found in 11% of 85 men who had nongonococcal urethritis, but was absent in a control group of 27 men. Clinical findings in ten men with symptomatic genitourinary trichomoniasis are described; all but one had relatively high (greater than or equal to 1:80) IHA antibody titers. Antibody to T. vaginalis was found significantly (P less than 0.005) more often in sera from women than in sera from men in an apparently healthy group of individuals between the ages of 1 and 20 years. The IHA test appears potentially useful for the diagnosis of trichomoniasis in men and in the seroepidemiology of infections due to T. vaginalis.

Evaluation Studies as Topic↗
PubMedDate not supplied

Screening for Trichomonas vaginalis infection by use of acridine orange fluorescent microscopy.

The acridine orange test for detection of Trichomonas vaginalis in smears has been adapted for delayed examination of specimens. Mailed-in slides stained by acridine orange were compared with on-site wet mounts; the acridine orange test detected 96% of all positives, whereas only 76% were detected by wet mounts. In a similar comparison with Papanicolaou smears, the acridine orange test detected 89% as compared with 67% detected by Papanicolaou smears.

Acridine Orange↗